+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Subcutaneous Immunoglobulin Market by Indication, End User, Delivery Mode, Formulation, Strength - Global Forecast to 2030- Product Image
Subcutaneous Immunoglobulin Market by Indication, End User, Delivery Mode, Formulation, Strength - Global Forecast to 2030- Product Image
Sale

Subcutaneous Immunoglobulin Market by Indication, End User, Delivery Mode, Formulation, Strength - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5889355
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Subcutaneous Immunoglobulin Market grew from USD 10.46 billion in 2024 to USD 11.63 billion in 2025. It is expected to continue growing at a CAGR of 10.91%, reaching USD 19.48 billion by 2030.

Unveiling the Critical Role of Subcutaneous Immunoglobulin in Modern Healthcare

Subcutaneous immunoglobulin has emerged as a transformative therapy, redefining treatment paradigms for patients with immunodeficiencies and other immune-mediated disorders. Against a backdrop of evolving clinical protocols and widening therapeutic applications, the importance of delivering immunoglobulin via the subcutaneous route has never been clearer. This introduction sets the stage for an in-depth exploration of the structural shifts, policy impacts, segmentation nuances, and competitive forces that are shaping the future of this essential treatment.

By highlighting key drivers such as enhanced patient autonomy, reduced infusion-related complications, and growing home-care adoption, this section underscores why stakeholders across clinical, commercial, and regulatory spheres must recalibrate their strategies. We will also outline how recent changes in trade policy, coupled with emerging manufacturing innovations, have introduced both challenges and unprecedented opportunities for market participants.

Emerging Paradigms Shaping the Subcutaneous Immunoglobulin Landscape

Innovation and adaptation have become the cornerstones of the subcutaneous immunoglobulin market’s evolution. Recent advances in formulation technology have produced more stable, higher-concentration products that simplify dosing regimens and reduce infusion times, enabling broader use beyond specialized hospital settings. At the same time, the shift from institutionalized treatment to home-based care has empowered patients to self-manage their therapy, improving adherence and quality of life.

This transformation is mirrored in the expanding scope of indications, where primary and secondary immunodeficiencies are no longer the sole focus. Clinical trials are increasingly targeting autoimmune and inflammatory conditions, opening doors for novel formulations delivered through both manual injection and advanced pump systems. The convergence of patient-centric delivery models with precision dosing underscores a new era in immunoglobulin therapy-one that emphasizes flexibility, convenience, and optimized clinical outcomes.

Assessing the Ripple Effects of New US Tariffs on Immunoglobulin Access

The introduction of new United States tariffs on imported immunoglobulin products in early 2025 has reverberated across the supply chain, prompting stakeholders to reevaluate sourcing, pricing, and inventory strategies. Manufacturers with domestic production capabilities have seen a relative cost advantage, while import-reliant distributors face margin compression that may translate into higher out-of-pocket expenses for patients.

This policy shift has also catalyzed a realignment of global procurement channels. Suppliers are negotiating long-term agreements to secure more favorable terms, while end users are exploring alternative formulations and strengths to mitigate budgetary pressures. The cumulative result is an ecosystem in flux-where tariff-induced cost pressures intersect with clinical imperatives to maintain uninterrupted patient access. Understanding these dynamics is critical for any organization seeking to navigate the new trade landscape without compromising on service quality or therapeutic efficacy.

Decoding Market Dynamics Through Multifaceted Segmentation Insights

Segmenting the subcutaneous immunoglobulin market reveals intricate patterns of demand rooted in distinct clinical and usage profiles. Across immunodeficiency indications, products tailored to primary conditions such as common variable immunodeficiency and X linked agammaglobulinemia command a stable patient base, while formulations designed for secondary immunodeficiency scenarios-whether chemotherapy induced or arising from hematological disorders-are experiencing incremental uptake as oncological and hematology treatment regimens expand.

When analyzing end users, a divergence emerges between clinic, home healthcare, and hospital channels. In general practice and specialist clinics, care providers favor high-concentration liquid formulations for rapid administration, whereas in nurse-assisted and self-administered home settings, ease of use and stability profile drive the adoption of lyophilized products. Community and tertiary hospitals, by contrast, prioritize pump-administered delivery modes to optimize infusion accuracy in high-volume treatment centers.

Delivery preferences further refine the market outlook. While manual injection remains the predominant mode for patients seeking autonomy, the growing acceptance of pump administered systems underscores a shift towards tailored infusion protocols. The interplay between liquid and lyophilized formulations, coupled with the choice between 10 percent and 20 percent strengths, highlights the importance of product versatility in satisfying the nuanced needs of diverse patient populations.

Geographical Nuances Driving Subcutaneous Immunoglobulin Adoption

Across the Americas, robust healthcare infrastructures and established reimbursement frameworks have supported widespread adoption of subcutaneous immunoglobulin, with mature markets in North America serving as benchmarks for patient access and clinical guidelines. In Europe, markets are characterized by nuanced regulatory approaches and centralized procurement models that influence pricing dynamics, while the Middle East and Africa are witnessing nascent growth driven by selective public-private partnerships and rising awareness of primary immunodeficiency disorders.

The Asia-Pacific region presents a mosaic of opportunities and challenges, where high-growth economies are investing in specialized care centers, even as cost containment pressures persist in markets reliant on public funding. Variations in cold-chain logistics capabilities, healthcare provider training, and tariff structures underscore the need for tailored commercial strategies that account for regional idiosyncrasies. Together, these regions illustrate how geographic context shapes product uptake, competitive positioning, and long-term market trajectories.

Competitive Landscape: Profiles of Leading Immunoglobulin Innovators

The competitive arena encompasses multinational pharmaceutical leaders, specialized biotech companies, and innovative contract manufacturing organizations. Market incumbents with integrated manufacturing capacities are leveraging scale economies to offer competitive pricing, while newcomers differentiate through proprietary formulation technologies and novel delivery systems. Strategic alliances between product innovators and distribution networks are accelerating time-to-market, particularly for high-concentration formulations and user-friendly administration kits.

Intellectual property portfolios and regulatory approvals vary significantly among players, with some focusing on continuous incremental improvements to established products and others pursuing breakthrough therapies designed to expand the spectrum of treatable conditions. Observing how these companies navigate pricing pressures, reimbursement hurdles, and tariff-induced cost variances will be instrumental in predicting which organizations will sustain leadership and which will cede ground to more agile entrants.

Strategic Imperatives for Industry Stakeholders in an Evolving Market

Industry leaders must prioritize agility and collaboration to thrive in a market defined by regulatory shifts and evolving patient expectations. Investing in modular manufacturing facilities can mitigate tariff-related cost volatility by enabling localized production closer to key end-user clusters. Simultaneously, partnerships with home-care service providers and digital health platform vendors can bolster patient adherence through remote monitoring and telehealth-enabled infusion support.

To capitalize on segmentation insights, executives should tailor their portfolios by indication, delivery mode, and formulation strength, ensuring that product offerings align with the specific needs of primary versus secondary immunodeficiency patients and the varying competencies of clinic, hospital, and home-care channels. Finally, maintaining open dialogue with policymakers and payers will be critical for influencing future tariff reviews and reimbursement frameworks, safeguarding both affordability and access.

Rigorous Methodology Underpinning the Subcutaneous Immunoglobulin Report

This analysis draws on a blend of primary and secondary research methodologies to deliver a rigorous assessment of the subcutaneous immunoglobulin landscape. Expert interviews with clinicians, payers, and manufacturing executives provided qualitative insights into clinical preferences, policy impacts, and operational challenges. Secondary data sources included peer-reviewed journals, regulatory filings, and publicly available trade databases, ensuring comprehensive coverage of market drivers and constraints.

Our segmentation framework was validated through cross-referencing patient registry data, treatment guidelines, and end-user procurement volumes across clinic, home healthcare, and hospital settings. Regional analyses incorporated tariff schedules, reimbursement policies, and cold-chain logistics assessments to map market entry barriers and growth prospects. Competitive profiling leveraged company financial reports, patent filings, and partnership announcements to gauge strategic priorities and innovation pipelines.

Conclusive Perspectives on Future Directions for Immunoglobulin Therapies

Subcutaneous immunoglobulin is poised to redefine therapeutic standards through its adaptability to diverse clinical environments and patient preferences. As cost pressures and policy shifts continue to shape the supply chain, stakeholders who embrace data-driven segmentation strategies and invest in localized manufacturing will be best positioned to lead. The competitive battleground will revolve around balancing cost efficiency with clinical differentiation, as companies seek to expand indications and streamline delivery modalities.

Moving forward, advances in formulation stability, pump technologies, and integrated patient support systems will further broaden the scope of subcutaneous immunoglobulin applications. For decision-makers, the imperative is clear: align strategic planning with the evolving regulatory landscape, deepen collaboration across the value chain, and prioritize patient-centric innovation to sustain growth and improve therapeutic outcomes.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Indication
    • Primary Immunodeficiency
      • Common Variable Immunodeficiency
      • X Linked Agammaglobulinemia
    • Secondary Immunodeficiency
      • Chemotherapy Induced Immunodeficiency
      • Hematological Disorder Induced Immunodeficiency
  • End User
    • Clinic
      • General Practice
      • Specialist
    • Home Healthcare
      • Nurse Assisted
      • Self Administered
    • Hospital
      • Community
      • Tertiary Care
  • Delivery Mode
    • Manual Injection
    • Pump Administered
  • Formulation
    • Liquid
    • Lyophilized
  • Strength
    • 10 Percent
    • 20 Percent
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • CSL Behring AG
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Grifols S.A.
  • Biotest AG
  • Kedrion S.p.A.
  • Green Cross Corporation
  • Bio Products Laboratory Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Subcutaneous Immunoglobulin Market, by Indication
8.1. Introduction
8.2. Primary Immunodeficiency
8.2.1. Common Variable Immunodeficiency
8.2.2. X Linked Agammaglobulinemia
8.3. Secondary Immunodeficiency
8.3.1. Chemotherapy Induced Immunodeficiency
8.3.2. Hematological Disorder Induced Immunodeficiency
9. Subcutaneous Immunoglobulin Market, by End User
9.1. Introduction
9.2. Clinic
9.2.1. General Practice
9.2.2. Specialist
9.3. Home Healthcare
9.3.1. Nurse Assisted
9.3.2. Self Administered
9.4. Hospital
9.4.1. Community
9.4.2. Tertiary Care
10. Subcutaneous Immunoglobulin Market, by Delivery Mode
10.1. Introduction
10.2. Manual Injection
10.3. Pump Administered
11. Subcutaneous Immunoglobulin Market, by Formulation
11.1. Introduction
11.2. Liquid
11.3. Lyophilized
12. Subcutaneous Immunoglobulin Market, by Strength
12.1. Introduction
12.2. 10 Percent
12.3. 20 Percent
13. Americas Subcutaneous Immunoglobulin Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Subcutaneous Immunoglobulin Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Subcutaneous Immunoglobulin Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. CSL Behring AG
16.3.2. Takeda Pharmaceutical Company Limited
16.3.3. Octapharma AG
16.3.4. Grifols S.A.
16.3.5. Biotest AG
16.3.6. Kedrion S.p.A.
16.3.7. Green Cross Corporation
16.3.8. Bio Products Laboratory Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. SUBCUTANEOUS IMMUNOGLOBULIN MARKET MULTI-CURRENCY
FIGURE 2. SUBCUTANEOUS IMMUNOGLOBULIN MARKET MULTI-LANGUAGE
FIGURE 3. SUBCUTANEOUS IMMUNOGLOBULIN MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. SUBCUTANEOUS IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COMMON VARIABLE IMMUNODEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY X LINKED AGAMMAGLOBULINEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CHEMOTHERAPY INDUCED IMMUNODEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL DISORDER INDUCED IMMUNODEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY GENERAL PRACTICE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALIST, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NURSE ASSISTED, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SELF ADMINISTERED, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COMMUNITY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY TERTIARY CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY MANUAL INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PUMP ADMINISTERED, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY 10 PERCENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY 20 PERCENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 59. CANADA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 60. CANADA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 61. CANADA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 62. CANADA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. CANADA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 64. CANADA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 65. CANADA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 66. CANADA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 67. CANADA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 68. CANADA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 69. MEXICO SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 70. MEXICO SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 71. MEXICO SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 72. MEXICO SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. MEXICO SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 74. MEXICO SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 75. MEXICO SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 76. MEXICO SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 77. MEXICO SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 78. MEXICO SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 120. GERMANY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 121. GERMANY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 122. GERMANY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 123. GERMANY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. GERMANY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 125. GERMANY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 126. GERMANY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 127. GERMANY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 128. GERMANY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 129. GERMANY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 130. FRANCE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 131. FRANCE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 132. FRANCE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 133. FRANCE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. FRANCE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 135. FRANCE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 136. FRANCE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 137. FRANCE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 138. FRANCE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 139. FRANCE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 143. RUSSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. RUSSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 145. RUSSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 146. RUSSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 147. RUSSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 148. RUSSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 150. ITALY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 151. ITALY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 152. ITALY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 153. ITALY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. ITALY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 155. ITALY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 156. ITALY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 157. ITALY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 158. ITALY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 159. ITALY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 160. SPAIN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 161. SPAIN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 162. SPAIN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 163. SPAIN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. SPAIN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 165. SPAIN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 166. SPAIN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 167. SPAIN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 168. SPAIN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 169. SPAIN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 170. UNITED ARAB EMIRATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 171. UNITED ARAB EMIRATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 172. UNITED ARAB EMIRATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 173. UNITED ARAB EMIRATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. UNITED ARAB EMIRATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 175. UNITED ARAB EMIRATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 176. UNITED ARAB EMIRATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 177. UNITED ARAB EMIRATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 180. SAUDI ARABIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 181. SAUDI ARABIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 182. SAUDI ARABIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 183. SAUDI ARABIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. SAUDI ARABIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 185. SAUDI ARABIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 186. SAUDI ARABIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 187. SAUDI ARABIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 188. SAUDI ARABIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 190. SOUTH AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 191. SOUTH AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 192. SOUTH AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 193. SOUTH AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. SOUTH AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 195. SOUTH AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 196. SOUTH AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 197. SOUTH AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 200. DENMARK SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 201. DENMARK SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 202. DENMARK SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 203. DENMARK SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. DENMARK SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 205. DENMARK SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 206. DENMARK SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 207. DENMARK SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 208. DENMARK SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 209. DENMARK SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 210. NETHERLANDS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 211. NETHERLANDS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 212. NETHERLANDS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 213. NETHERLANDS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. NETHERLANDS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 215. NETHERLANDS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 216. NETHERLANDS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 217. NETHERLANDS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 218. NETHERLANDS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 219. NETHERLANDS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 220. QATAR SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 221. QATAR SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 222. QATAR SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 223. QATAR SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. QATAR SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 225. QATAR SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 226. QATAR SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 227. QATAR SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 228. QATAR SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 229. QATAR SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 230. FINLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 231. FINLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 232. FINLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 233. FINLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. FINLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 235. FINLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 236. FINLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 237. FINLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 238. FINLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 239. FINLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 240. SWEDEN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 241. SWEDEN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 242. SWEDEN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 243. SWEDEN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. SWEDEN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 245. SWEDEN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 246. SWEDEN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 247. SWEDEN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 250. NIGERIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 251. NIGERIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 252. NIGERIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 253. NIGERIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. NIGERIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 255. NIGERIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 256. NIGERIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 257. NIGERIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 258. NIGERIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 259. NIGERIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 260. EGYPT SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 261. EGYPT SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 262. EGYPT SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 263. EGYPT SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. EGYPT SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 265. EGYPT SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 266. EGYPT SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 267. EGYPT SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 268. EGYPT SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 269. EGYPT SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 270. TURKEY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 271. TURKEY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 272. TURKEY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 273. TURKEY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. TURKEY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 275. TURKEY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 276. TURKEY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 277. TURKEY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 278. TURKEY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 279. TURKEY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 280. ISRAEL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 281. ISRAEL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 282. ISRAEL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 283. ISRAEL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 284. ISRAEL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 285. ISRAEL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 286. ISRAEL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 287. ISRAEL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 288. ISRAEL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 289. ISRAEL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 290. NORWAY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 291. NORWAY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 292. NORWAY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 293. NORWAY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. NORWAY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 295. NORWAY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 296. NORWAY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 297. NORWAY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 298. NORWAY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 299. NORWAY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 300. POLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 301. POLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 302. POLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 303. POLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 304. POLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 305. POLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 306. POLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 307. POLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 308. POLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 309. POLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 310. SWITZERLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 311. SWITZERLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 312. SWITZERLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, 2018-2030 (USD MILLION)
TABLE 313. SWITZERLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 314. SWITZERLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 315. SWITZERLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 316. SWITZERLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018

Companies Mentioned

The companies profiled in this Subcutaneous Immunoglobulin market report include:
  • CSL Behring AG
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Grifols S.A.
  • Biotest AG
  • Kedrion S.p.A.
  • Green Cross Corporation
  • Bio Products Laboratory Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages188
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11.63 Billion
Forecasted Market Value ( USD ) by 2030 $ 19.48 Billion
Compound Annual Growth Rate10.9%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Reports

Immunoprotein Market by Product, Application, End User, Technology, Distribution Channel - Global Forecast to 2030 - Product Image

Immunoprotein Market by Product, Application, End User, Technology, Distribution Channel - Global Forecast to 2030

  • Report
  • 189 Pages
  • Global
From
Subcutaneous Immunoglobulin - Global Strategic Business Report - Product Image

Subcutaneous Immunoglobulin - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Plasma Protein Therapeutics Market by Product, Indication, Route of Administration, End User - Global Forecast to 2030 - Product Image

Plasma Protein Therapeutics Market by Product, Indication, Route of Administration, End User - Global Forecast to 2030

  • Report
  • 182 Pages
  • Global
From
Subcutaneous Immunoglobulin (SCIG) Market Report 2025 - Product Image

Subcutaneous Immunoglobulin (SCIG) Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Immunoglobulin Market Report by Product, Mode of Delivery, and Region 2024-2032 - Product Image

Immunoglobulin Market Report by Product, Mode of Delivery, and Region 2024-2032

  • Report
  • 140 Pages
  • Global
From

About the Market

The Subcutaneous Immunoglobulin (SCIg) market is a segment of the Immune Disorders Drugs market. SCIg is a form of immunoglobulin therapy used to treat a variety of immune-mediated diseases, such as primary immunodeficiencies, autoimmune diseases, and chronic inflammatory diseases. SCIg is administered through subcutaneous injections, which are less painful and more convenient than intravenous infusions. SCIg is also more cost-effective than intravenous immunoglobulin (IVIg). SCIg is a rapidly growing market, driven by the increasing prevalence of immune-mediated diseases and the growing demand for more convenient and cost-effective treatments. The market is expected to continue to grow in the coming years, as more patients are diagnosed with immune-mediated diseases and as new treatments become available. Some of the major players in the SCIg market include CSL Behring, Grifols, Kedrion, Octapharma, and Shire. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.